SCREENING STUDIES OF THE HYPOGLYCEMIC EFFECT OF A PHYTOCOMPOSITION BASED ON POLYPHENOLIC EXTRACT FROM CRANBERRY LEAVES AND AMINO ACIDS

Abstract

Formulation of the problem. Diabetes mellitus today is one of the main medical and social problems in the world and in Ukraine. More than 90% are patients with type 2 diabetes, the treatment of which should be focused on the pathophysiological mechanisms of development, complex, affecting metabolic disorders that lead to the development of severe chronic disabling complications. Analysis of recent research and publications. A promising direction is the development of combined products based on plant materials with the addition of amino acids, which can be effective as mono drugs and in complex therapy together with hypoglycemic agents. Cranberry leaves (Vaccinium macrocarpon) are a source of valuable biologically active substances. The amino acids L-arginine, taurine and glycine have a number of biological effects necessary for antidiabetic therapy. Formulation of the aim of the article. The aim of this work was to screen the hypoglycemic effect of a phytocomposition based on a polyphenolic extract from the leaves of Cranesbillus americana and the amino acids L-arginine, taurine and glycine. Presentation of the main research material. A screening study of hypoglycemic action was performed on normoglycemic rats and rats with impaired glucose tolerance caused by subcutaneous injections of the glucocorticoid dexamethasone. Arfazetin and metformin tablets were used as comparison drugs. The hypoglycemic effect of the phytocomposition was determined by the dynamics of glucose during the oral glucose tolerance test and the areas under the glycemic curves. When the phytocomposition was administered to normoglycemic rats for 14 days, its hypoglycemic effect began to manifest itself reliably at a dose of 100 mg/ kg and remained stable at a higher dose of 125 mg/kg. On the model of impaired glucose tolerance, the phytocomposition at doses of 100 and 125 mg/kg exhibits a pronounced antihyperglycemic effect, which is superior to the antidiabetic phytocompound “Arfazetin” and not inferior to metformin tablets. Since the phytocomposition in doses of 100 and 125 mg/kg showed almost the same suppression of hyperglycemia, it is advisable to use a dose of 100 mg/kg as a conditionally therapeutic dose in further studies. Conclusions. As a result of pharmacological screening, a conditionally therapeutic dose of 100 mg/kg was established in normoglycemic rats and animals with impaired glucose tolerance during the oral glucose tolerance test, which causes a pronounced and reliable antihyperglycemic effect, when using a phytocomposition based on a polyphenolic extract from the leaves of cranberry large-fruited and amino acids. In terms of the severity of antihyperglycemic action, the phytocomposition at a dose of 100 mg/kg is not inferior to metformin and significantly exceeds the effect of the phytocollection “Arfazetin” by 1.4 times. The results obtained are the basis for an in-depth study of the phytocomposition at a dose of 100 mg/kg as an antidiabetic agent.